Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Povidone Iodine: 2% Povidone Iodine gargle diluted to 1% (w/v) is used as oropharyngeal gargle and intranasal application given 4 times to 48 laboratory tested COVID-19 patients and fol
Sponsors
WIN MEDICARE PVTLTD
Eligibility
Inclusion criteria
Inclusion criteria: All patients laboratory tested COVID-19 positive above 18 years of age +/- two days of admission
Exclusion criteria
Exclusion criteria: Known allergy to povidone iodine or iodine thyroid disorders pregnancy patients on Lithium therapy patients on respiratory distress / unconscious / on ventilator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| comparing the reduction in the progression, transmission of disease in 48 participants taking oropharyngeal gargles and intranasal application of PVP-I in comparison to the control group not doing the same for which patients in both the group will be tested for viral load on 7 th and 21 st day. Spread of the disease can be checked by confirming if the nasal / oropharyngeryngel swabs turn negative and no contacts turn covid-19 positiveTimepoint: The study group will be tested for covid-19 to check for negativity on & 7th and 21st day following intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Early recovery from infection and no relapse of infection. patients will be tested on 7th day and 21st day to confirm if they have turned negative . early negative will be an indicative of early recovery. Also even if any of the patients have co morbid factors and they do not turn serious that will suggest that disease progression is controlledTimepoint: 12 to 14 weeks | — |
Countries
India
Contacts
Public ContactDr Sumita Shankar
Rangaraya Medical College
Outcome results
None listed